Finasteride works for male pattern hair loss. The trials are clear on that. But if you have read anything online about it, you have probably hit two extremes: forums describing it as a drug that ruined people's lives, and slick ads implying it is harmless. Neither extreme is accurate, and you deserve the actual numbers so you can make a real decision. This post lays out what the trials measured, what the controversy is about, and what regulators concluded in 2025.

What Finasteride Does

Finasteride blocks the enzyme type II 5-alpha-reductase, which converts testosterone into dihydrotestosterone (DHT). DHT is the hormone that miniaturizes scalp follicles in genetically susceptible men. On the 1 mg hair-loss dose, serum DHT drops roughly 70 percent, which halts or partly reverses the miniaturization. (Dutasteride suppresses more DHT still, which is the basis for the step-up question.) The same DHT suppression is the reason for the sexual side effects, because DHT has roles beyond the scalp.

The Sexual Side Effect Numbers From the Trials

This is the part people most want quantified. In the pivotal trials of finasteride 1 mg for hair loss (Kaufman et al., J Am Acad Dermatol 1998), the sexual side effects reported were:

  • Decreased libido: about 1.8 percent on finasteride versus about 1.3 percent on placebo
  • Erectile dysfunction: about 1.3 percent on finasteride versus about 0.7 percent on placebo
  • Decreased ejaculate volume or ejaculation disorder: about 1.2 percent on finasteride versus about 0.7 percent on placebo

Two honest readings of these numbers. First, the rates are low in absolute terms, in the low single digits. Second, the placebo rates are not zero, which means some men report these symptoms on a sugar pill, and the true drug-attributable rate is the difference between the two columns, not the finasteride column alone. In the trials, most men who had a sexual side effect saw it resolve while continuing the drug or after stopping it.

It is worth saying plainly that real-world reporting tends to run higher than tightly controlled trials, partly because of awareness and partly because trials may under-capture. The trial numbers are the floor of what is known, not the ceiling of what is possible.

Gynecomastia and Other Effects

Breast tenderness or enlargement (gynecomastia) is reported but uncommon. Any new breast lump should be evaluated rather than assumed benign. Finasteride also lowers PSA, the prostate screening marker, by roughly 50 percent, so if you are over 40 and getting prostate screening, tell whoever interprets the result to double your PSA value. This is a lab-interpretation issue, not a side effect, but it matters.

Post-Finasteride Syndrome: The Honest Version

The hardest part of the finasteride conversation is post-finasteride syndrome (PFS). This is the name given to a cluster of sexual, neurological and mood symptoms that some men report persisting after they stop the drug, sometimes for months or years. The reported symptoms include persistent erectile dysfunction, loss of libido, genital numbness, brain fog and depression.

Here is the fair framing. The mechanism of PFS is not established, and there is no diagnostic test for it. Some researchers question whether it is a distinct drug-caused syndrome or whether other factors contribute. At the same time, the reports are consistent enough, and come from enough men, that dismissing them is not honest either. Regulators have treated the signal as real enough to act on. The responsible position is that persistent symptoms after stopping appear to be uncommon, the cause is contested, and the possibility is worth knowing about before you start. Anyone who tells you PFS is definitely fake, or definitely common, is overstating what the evidence supports.

The 2025 EMA Suicidality Decision

In 2025, European regulators made a formal move on the mood question. After a EU-wide safety review, the European Medicines Agency's pharmacovigilance committee (PRAC) concluded in May 2025 that suicidal ideation should be recognized as a side effect of finasteride tablets, and the European Commission issued a binding decision in August 2025 directing updated product information across member states.

The specifics, stated accurately: the frequency was classified as unknown, meaning the data did not allow an estimate of how often it happens. Most reported cases were in men using the 1 mg hair-loss tablet rather than the 5 mg prostate dose. The committee concluded that the benefits of finasteride still outweigh the risks for its approved uses, while directing that patients be counseled to stop the drug and seek help if they develop mood changes or thoughts of self-harm. This sits alongside earlier FDA actions that added depression language (2011) and suicidality language (2022) to US labeling.

The practical takeaway is not that finasteride causes suicide at a measurable rate, because the data do not show a rate. It is that a recognized association exists, that mood symptoms are a reason to stop and seek care promptly, and that anyone with a history of depression should weigh this carefully with a clinician before starting. (Finasteride is also restricted for women who could become pregnant for a separate reason.)

A Note on Compounded Topical Finasteride

Some telehealth services sell compounded topical finasteride as a "lower side effect" alternative. Be cautious with that claim. In 2025 the FDA issued an alert on compounded topical finasteride after reports of systemic side effects, including erectile dysfunction, anxiety, suicidal ideation, brain fog, depression and libido loss, in people using the topical form. Topical finasteride still gets absorbed, and the compounded products lack the safety dossier of the oral drug. "Topical" does not reliably mean "no systemic effect."

How to Decide

Finasteride is effective and, for most men, well tolerated. The trial rates of sexual side effects are in the low single digits and partly overlap with placebo. The harder issues, persistent symptoms after stopping and the recognized mood signal, are real considerations rather than internet myths, and they deserve an honest conversation rather than reassurance or alarm.

Before starting, take stock of two things: your own history of depression, anxiety or suicidal thoughts, and your tolerance for the small but nonzero chance of sexual side effects. Discuss both with a clinician, agree on what would make you stop, and know that the drug's effect, good and bad, depends on continued use. Discontinuation reverses the hair benefit within six to twelve months.

Reviewed By

[Reviewed by: clinician name, credential. Last reviewed: date.]

Want to weigh finasteride against your own history before deciding? Start an intake and a licensed clinician will review your risk factors and counsel you on the real tradeoffs.

This article is for education and is not a substitute for individual medical advice from your own clinician.